Trial Profile
A Randomized, Open-label Study to Characterize the Pharmacokinetics of Inhaled Oxytocin (GR121619) Compared With IM Oxytocin in Women in the Third Stage of Labour, and With IV Oxytocin in Non-pregnant, Non-lactating Women of Childbearing Potential
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 07 Sep 2023
Price :
$35
*
At a glance
- Drugs Oxytocin (Primary) ; Oxytocin (Primary) ; Oxytocin (Primary)
- Indications Postpartum haemorrhage
- Focus Adverse reactions; Pharmacokinetics
- Sponsors GlaxoSmithKline; GSK
- 27 Mar 2019 Status changed from recruiting to discontinued.
- 15 Feb 2019 Planned End Date changed from 24 Dec 2018 to 3 May 2019.
- 15 Feb 2019 Planned primary completion date changed from 24 Dec 2018 to 3 May 2019.